At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 201 enrolled
Drug / intervention
Brexpiprazoledrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Adult Subjects With Borderline Personality Disorder
Otsuka Pharmaceutical Development & Commercialization, Inc.·interventional·Posted Dec 4, 2019·Updated Oct 3, 2024
In Brief
A Phase 3 clinical trial evaluating Brexpiprazole for Borderline Personality Disorder. Completed, enrolled 201 participants across 1 site.
Detailed Summary
This study evaluates the safety and tolerability of brexpiprazole in the treatment of adults with borderline personality disorder.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBorderline Personality Disorder
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
2020202120222023202420252026
First PostedDec 2019
Enrollment StartJan 2020
Primary CompletionSep 2021
TodayJul 2026
First PostedDec 4, 2019
Enrollment StartJan 13, 2020
Primary CompletionSep 22, 2021
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 6.6 years ago
Interventions
Brexpiprazoledrug
Administered as tablets.